Profilo
Akintunde Bello is currently Director at Xilio Therapeutics, Inc. since 2025.
Formerly, Dr. Bello was SVP, Head-Pharmacology & Bioanalysis at Bristol Myers Squibb Co. Education includes a doctorate from King's College London, a graduate degree from The University of Manchester, and an undergraduate degree from the University of Portsmouth.
Posizioni attive di Akintunde Bello
| Società | Posizione | Inizio |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 10/06/2025 |
Precedenti posizioni note di Akintunde Bello
| Società | Posizione | Fine |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2025 |
Formazione di Akintunde Bello
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
The University of Manchester
The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
















